<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Trials</title>
    <link rel="stylesheet" href="style.css" type="text/css">
</head>

<body>
    <header class="top-content">
        <div class="header head-item">Hepion Pharmaceuticals (NASDAQ:HEPA)</div>
        <div class="nav head-item">
            <div class="nav-item"><a href="index.html">Summary</a></div>
            <div class="nav-item"><a href="factsheet.html">Articles</a></div>
            <div class="nav-item"><a href="trial.html" id="location">Trials</a></div>
        </div>
    </header>

    <section class="preview">
        <div class="preview-item preview-left">"TACKLING CHRONIC LIVER DISEASE:<br>NASH, Hepatitis, Cirrhosis, Liver
            Failure, and Cancer."</div>
        <div class="preview-item preview-right">"Hepion Pharmaceuticals is a clinical stage biopharmaceutical company
            focused on Artificial Intelligence driven therapeutic drug development for the treatment of non-alcoholic
            steatohepatitis, fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases."</div>
    </section>
    <h1 class="watermark">CapriceYuri</h1>

    <section class="img">
        <img class="animation cycle-a" src="image/cycleA.gif" alt="Cyclophilin A">
        <img class="animation cycle-b" src="image/cycleB.gif" alt="Cyclophilin B">
        <img class="animation cycle-d" src="image/cycleD.gif" alt="Cyclophilin D">
    </section>

    <section class="trial-main">
        <br>
        <h1>Pre-Clinical & Clinical Trials</h1><br>

        <br><br>
        <div class="trial-point-header trial-style">P2A ASPIRE - HCC</div>
        <div class="trial-status trial-style upcoming">Status: Upcoming</div>
        <div class="trial-point-content trial-style"><br>Summary: Assess the prelimiary efficacy, safety, and
            pharmacokinetics of Rencofilstat in Advanced Hepatocellular Carcinoma patients.</div>

        <br>
        <div class="trial-point-header trial-style">ADME - [14C]</div>
        <div class="trial-status trial-style upcoming">Status: Upcoming</div><br>
        <div class="trial-point-content trial-style"><br>Summary: Evaluate the absorption, distribution, metabolism, and
            excretion of Rencofilstat in healthy male patients.</div>

        <br>
        <div class="trial-point-header trial-style">P2B ASCEND - NASH</div>
        <div class="trial-status trial-style">Status: In-Progress</div>
        <div class="trial-point-content trial-style"><br>Summary: Evaluate the safety, tolerability, and efficacy of
            Rencofilstat in adult patients with NASH and Advanced Liver Fibrosis.<br><br>Details: Enrollment of 336
            pacticipants, each cohort consists of 84 patients with biopsy proven NASH F2/F3. Patients will be dose in a
            1:1:1:1 ratio between Rencofilstat 75mg, 150mg, 225mg, and matching placebo. The duration of dosing will be
            1 year with 1 month observation and follow up period.<br><br>Endpoints: Efficacy, superiority of
            Rencofilstat compared to placebo and assessing the proportion of patients with improvement in fibrosis OR
            NASH resolution without worsening of fibrosis.</div><br>

        <br>
        <div class="trial-point-header trial-style">P2 ALTITUDE - NASH</div>
        <div class="trial-status trial-style">Status: In-Progress</div>
        <div class="trial-status trial-style partner">Collaboration: HepQuant</div>
        <div class="trial-point-content trial-style"><br>Summary: Evaluate the safety, tolerability, and efficacy of
            Rencofilstat in adult patients with NASH F3.<br><br>Details: Enrollment of 60 participants, each cohort
            consists of 20 patients classified as NASH F2/F3 based on either historical biopsy or by using AGILE 3+
            criteria. Patients will be dose in a 1:1:1 ratio between Rencofilstat 75mg, 150mg, and 225mg. The duration
            of dosing will be 120 days with follow up period of 14 days.<br>The study will use HepQuant's SHUNT test,
            which provides sensitive measurement of hepatic function and detailed information on the role Rencofilstat
            plays in liver health in NASH patients with advance fibrosis. The SHUNT test will be performed at days 1,
            60, and 120.<br><br>Endpoints: Efficacy - HepQuant SHUNT, Safety, Tolerability, and Pharmacokinetics.</div>
        <br>

        <br>
        <div class="trial-point-header trial-style">P2A AMBITION - NASH</div>
        <div class="trial-status trial-style completion">Status: Completed</div>
        <div class="trial-point-content trial-style"><br>Summary: Evaluate the safety and tolerability of Rencofilstat
            in patients with F2/F3 NASH.<br><br>Details: Enrollment of 43 participants. Patients will be dose once daily
            in 12:6:17:8 ratio between 75mg, 75mg placebo, 225mg, and 225mg placebo, respectively. The duration of dosing
            will be 28 days with follow up period of 14 days and non-invasive anti-fibrotic biomarkers will be
            collected.<br><br> Endpoints: Safety, Tolerability, and Pharmacokinetics.</div><br>

        <br>
        <div class="trial-point-header trial-style">CRV431-101</div>
        <div class="trial-status trial-style completion">Status: Completed</div>
        <div class="trial-point-content trial-style"><br>Summary: A three part study:<br> Part One: Assess safety,
            tolerability, and pharmacokinetics of a single does of Rencofilstat in healthy volunteers.<br> Part Two:
            Study the drug-drug interaction of a single does Rencofilstat in healthy volunteers, in combination with
            Tenofovir Disoproxil Fumarate.<br> Part Three: Assess safety, tolerability, pharmacokinetics, and prelimiary
            signal for antiviral efficacy in stable HBV patients.
        </div><br>

        <br>
        <div class="trial-point-header trial-style">CRV431-103</div>
        <div class="trial-status trial-style completion">Status: Completed</div>
        <div class="trial-point-content trial-style"><br>Summary: Evalute the pharmacokinetics of Rencofilstat in
            healthy volunteers, a drug-drug interaction study. </div><br>

        <br>
        <div class="trial-point-header trial-style">CRV431-104</div>
        <div class="trial-status trial-style completion">Status: Completed</div>
        <div class="trial-point-content trial-style"><br>Summary: Evaluate the pharmacokinetics of Rencofilstat under
            fasted and fed states in healthy volunteers.<br>Details: Enrollment of 44 healthy participants. Patients
            were assigned to either the fasted or the high-fat fed arm, 24 patients and 20 patients, respectively.</div>
        <br>
    </section>
</body>

</html>